Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
Last updated
72 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Bruton tyrosine kinase inhibitors

2 evidence topics · 2 sources

Relapsed or refractory PCNSL: EHA-ESMO guideline

“Tirabrutinib, a highly selective BTK inhibitor, is a valid option in this setting.” (opens the source at this quote in a new tab)

European Association of Neuro-Oncology guideline update

“signs of clinical activity of tirabrutinib, a second-generation BTK inhibitor, have also been found.” (opens the source at this quote in a new tab)